Chemed Corp. shares soared more than 10% in midday trading Friday, climbing to around $424 after the healthcare services company delivered a solid first-quarter 2026 earnings beat, highlighted by strong performance at its VITAS hospice business and an upgraded full-year outlook that exceeded Wall Street expectations.
The stock (NYSE: CHE) opened sharply higher and sustained robust gains on April 24, with trading volume well above average. The move reflects investor relief and enthusiasm following Chemed's report late Thursday, which showed resilience in its core end-of-life care operations amid a challenging environment for Medicare-funded services.
